Truscreen Group Ltd NZX:TRU:
MANAGEMENT UPDATE
MARTIN DILLON, CEO, GRANTED A THREE-MONTH LEAVE OF ABSENCE
TONY HO, NON-EXECUTIVE INDEPENDENT CHAIRMAN, WILL ASSUME EXECUTIVE RESPONSIBILITIES AS EXECUTIVE CHAIRMAN ON INTERIM BASIS
Truscreen Group Provides Management Update
Earlier from TruScreen
- TruScreen Validated as Superior Cervical Cancer Screening Tool in Major Chinese Study
- Truscreen Group Says It Signed First Uzbekistan Sales Contract
- TRU: Revenue down 17% in 1H FY2026, but growth expected from new programs and markets
- TRU: FY26 growth is forecast on public program expansion, new markets, and product diversification
- TRU: FY26 sales projected to surpass NZ$2.8m as public programs and new markets accelerate growth
Later from TruScreen
- Truscreen Group Sees Total Revenue For Fy2026 To Be Nz$2.7 Million
- Truscreen Says Submits Three Proposals To Unitaid's Global Cervical Cancer Elimination Call
- Truscreen Group Sees FY26 Unaudited Loss
- TRU: AI-driven cervical cancer screening device posts rapid sales growth and global expansion
- TRU: FY26 sales up 42% YOY, global expansion accelerates, and FY27 outlook remains robust
Follow TruScreen into a list and get an email when it puts out news.
Follow TruScreen